136 related articles for article (PubMed ID: 36270831)
41. How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?
Rovirosa A; Ascaso C; Ordi J; Arenas M; Valduvieco I; Lejarcegui JA; Pahisa J; Torne A; Biete A
Clin Transl Oncol; 2009 Oct; 11(10):681-7. PubMed ID: 19828411
[TBL] [Abstract][Full Text] [Related]
42. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
43. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
44. [Metastatic lung tumor from uterine leiomyosarcoma].
Nishida T; Shoji S; Itoh T; Minami H; Akizuki K; Ozuno I; Kageyama H; Ozaki I; Yamamoto K; Yamamoto A; Nishiyama N
Kyobu Geka; 2006 Dec; 59(13):1191-6. PubMed ID: 17163213
[TBL] [Abstract][Full Text] [Related]
45. Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases.
Lim D; Wang WL; Lee CH; Dodge T; Gilks B; Oliva E
Gynecol Oncol; 2013 Feb; 128(2):322-6. PubMed ID: 23153591
[TBL] [Abstract][Full Text] [Related]
46. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
[TBL] [Abstract][Full Text] [Related]
47. Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Simoni A; Taddei A; Taddei GL
J Chemother; 2003 Dec; 15(6):596-602. PubMed ID: 14998087
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
49. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
50. Prognostic factors and outcomes in 28 cases of uterine leiomyosarcoma.
Loizzi V; Cormio G; Nestola D; Falagario M; Surgo A; Camporeale A; Putignano G; Selvaggi L
Oncology; 2011; 81(2):91-7. PubMed ID: 21968290
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
[TBL] [Abstract][Full Text] [Related]
52. Construction and Validation of Nomograms for Predicting the Prognosis of Uterine Leiomyosarcoma: A Population-Based Study.
Meng Y; Yang Y; Zhang Y; Li X
Med Sci Monit; 2020 Apr; 26():e922739. PubMed ID: 32270788
[TBL] [Abstract][Full Text] [Related]
53. Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma.
Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Tergas AI; Hershman DL; Wright JD
Gynecol Oncol; 2021 Jun; 161(3):734-740. PubMed ID: 33810881
[TBL] [Abstract][Full Text] [Related]
54. Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma.
Nasioudis D; Chapman-Davis E; Frey M; Holcomb K
J Gynecol Oncol; 2017 Jul; 28(4):e46. PubMed ID: 28541635
[TBL] [Abstract][Full Text] [Related]
55. Undiagnosed Uterine Sarcomas Identified During Surgery for Presumed Leiomyoma at a National Tertiary Hospital in Thailand: A 10-Year Review.
Ruengkhachorn I; Phithakwatchara N; Nawapun K; Hanamornroongruang S
Int J Gynecol Cancer; 2017 Jun; 27(5):973-978. PubMed ID: 28498251
[TBL] [Abstract][Full Text] [Related]
56. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract][Full Text] [Related]
57. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
[TBL] [Abstract][Full Text] [Related]
58. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
59. Uterine leiomyosarcoma metastasizing to the heart.
Tunio MA; Al-Asiri M; Fareed MM
J Coll Physicians Surg Pak; 2014 Mar; 24 Suppl 1():S20-1. PubMed ID: 24717993
[TBL] [Abstract][Full Text] [Related]
60. Regression of uterine leiomyomata in response to the antiprogesterone RU 486.
Murphy AA; Kettel LM; Morales AJ; Roberts VJ; Yen SS
J Clin Endocrinol Metab; 1993 Feb; 76(2):513-7. PubMed ID: 8432797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
